SynthesisWorld journal of gastroenterology2014
Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Synthesis in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 38 citations in OpenAlex.
- Evaluating Cost-Effectiveness of 85 Endoscopic Surveillance Strategies of Nondysplastic Barrett's Esophagus.Journal of gastroenterology and hepatology · 2026Article
- Computing lifetime incidence of esophageal adenocarcinoma and age-specific prevalence of Barrett's esophagus.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- Factors influencing the cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia in Australia.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2025Article
- 'Why Don't We Get Counselling?': Comparing NICE Guidelines for Morphological and Genetic Cancer Risk Diagnoses.Cancer medicine · 2025Article
- Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer.Biomedicines · 2024Article
- First-in-human pilot study of snapshot multispectral endoscopy for early detection of Barrett's-related neoplasia.Journal of biomedical optics · 2021Article
- The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis.Gastroenterology · 2021Article
- Spectral Endoscopy Enhances Contrast for Neoplasia in Surveillance of Barrett's Esophagus.Cancer research · 2021Article
- Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma.Therapeutic advances in gastroenterology · 2021Review
- The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett's Esophagus Management.The American journal of gastroenterology · 2020Article
- Novel biomarkers for risk stratification of Barrett's oesophagus associated neoplastic progression-epithelial HMGB1 expression and stromal lymphocytic phenotype.British journal of cancer · 2020Article
- Invited Commentary to "The Gastric Migration Crisis in Obesity Surgery".Obesity surgery · 2019Article
- A roadmap for the clinical implementation of optical-imaging biomarkers.Nature biomedical engineering · 2019Review
- Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity.International journal of molecular sciences · 2019Review
- Gastrointestinal Tract Disorders in Older Age.Canadian journal of gastroenterology & hepatology · 2019Review
- Risk stratification for malignant progression in Barrett's esophagus: Gender, age, duration and year of surveillance.World journal of gastroenterology · 2016Article
- A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus.PLoS computational biology · 2016Article
- Article
- Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.Gastroenterology clinics of North America · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the lifetime risk of development of esophageal adenocarcinoma and/or high-grade dysplasia in patients diagnosed with Barrett's esophagus.
methodsData were extracted from the United Kingdom National Barrett's Oesophagus Registry on date of diagnosis, patient age and gender of 7877 patients from who had been registered from 35 United Kingdom centers. Life expectancy was evaluated from United Kingdom National Statistics data based upon gender and age at year at diagnosis. These data were then used with published estimates of annual adenocarcinoma and high-grade dysplasia incidences from meta-analyses and large population-based studies to estimate overall lifetime risk of development of these study endpoints.
resultsThe mean age at diagnosis of Barrett's esophagus was 61.6 years in males and 67.3 years in females. The mean life expectancy at diagnosis was 23.1 years in males, 20.7 years in females and 22.2 years overall. Using data from published meta-analyses, the lifetime risk of development of adenocarcinoma was between 1 in 8 and 1 in 14 and the lifetime risk of high-grade dysplasia or adenocarcinoma was 1 in 5 to 1 in 6. Using data from 3 large recent population-based cohort studies the lifetime risk of adenocarcinoma was between 1 in 10 and 1 in 37 and of the combined end-point of high-grade dysplasia and adenocarcinoma was between 1 in 8 and 1 in 20. Age at Barrett's esophagus diagnosis is reducing and life expectancy is increasing, which will partially counter-balance lower annual cancer incidence.
conclusionThere is a significant lifetime risk of development of high-grade dysplasia and adenocarcinoma in Barrett's esophagus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.